Xilio Therapeutics
24 hedge funds and large institutions have $22M invested in Xilio Therapeutics in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 19 closing their positions.
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
13% less capital invested
Capital invested by funds: $25.4M → $22M (-$3.4M)
30.37% less ownership
Funds ownership: 75.67% → 45.3% (-30%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
35% less funds holding
Funds holding: 37 → 24 (-13)
63% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$1.13M |
| 2 |
CP
Caligan Partners
New York
|
+$918K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$452K |
| 4 |
Renaissance Technologies
New York
|
+$204K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$112K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.56M |
| 2 |
SC
Stempoint Capital
New York
|
-$1.3M |
| 3 |
EAM
Empery Asset Management
New York
|
-$757K |
| 4 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
-$538K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$279K |
XLO Hedge Fund Activity: Q1 2026 in Review
24 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q1 2026, worth a combined $22M — down 13% from $25.4M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of XLO and 7 opened new positions — a net loss of 12 holders — while 8 trimmed existing stakes and 7 added.
The largest buyer was Bain Capital Life Sciences Investors, adding an estimated $1.13M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $2.56M sold.
- 24 institutional investors held Xilio Therapeutics (XLO) as of Q1 2026, down from 37 in Q4 2025.
- Funds reported $22M of Xilio Therapeutics stock for Q1 2026, down 13% quarter-over-quarter.
- 7 funds opened new Xilio Therapeutics positions in Q1 2026 and 19 closed out, a net change of -12 holders.
- The largest Xilio Therapeutics buyer in Q1 2026 was Bain Capital Life Sciences Investors, an estimated $1.13M added.
- The largest Xilio Therapeutics seller in Q1 2026 was Point72 Asset Management, an estimated $2.56M sold.
Based on aggregated 13F filings for Q1 2026.